DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Audeh MW, Carmichael J, Penson RT et al.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Lancet 2010;
376: 245-251
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.